Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Inactivated vaccines. 1. Volunteer studies with very high doses of influenza vaccine purified by zonal ultracentrifugation.

Mostow SR, Schoenbaum SC, Dowdle WR, Coleman MT, Kaye HS.

Postgrad Med J. 1973 Mar;49(569):152-8. No abstract available.

2.

Age-related response to 1000 CCA unit zonally purified, inactivated influenza vaccines in volunteers in the U.S.A.

Marine WM, Thomas JE.

Postgrad Med J. 1973 Mar;49(569):164-8. No abstract available.

3.

Influenza vaccines purified by zonal ultracentrifugation.

Filczak K, Semkow R, Wrzos H, Zakrzewski K, Zgorzelska K.

Acta Microbiol Pol A. 1973;5(3):261-70. No abstract available.

PMID:
4769561
4.

Studies with inactivated influenza vaccines purified by zonal centrifugation. 1. Adverse reactions and serological responses.

Mostow SR, Schoenbaum SC, Dowdle WR, Coleman MT, Kaye HS.

Bull World Health Organ. 1969;41(3):525-30.

5.

A new subunit influenza vaccine; acceptability compared with standard vaccines and antigenicity in increasing dosage.

Ruben FL, Jackson GG.

Postgrad Med J. 1973 Mar;49(569):185-92. No abstract available.

6.

A clinical and serologic comparison of standard and purified bivalent inactivated influenza vaccines.

Finklea JF, Sandifer SH, Peck FB, Manos JP.

J Infect Dis. 1969 Dec;120(6):708-12. No abstract available.

PMID:
4911903
7.

Studies on inactivated influenza vaccines. II. Effect of increasing dosage on antibody response and adverse reactions in man.

Mostow SR, Schoenbaum SC, Dowdle WR, Coleman MT, Kaye HS, Hierholzer JC.

Am J Epidemiol. 1970 Oct;92(4):248-56. No abstract available.

PMID:
5458217
8.

A surface antigen influenza vaccine. 2. Pyrogenicity and antigenicity.

Brady MI, Furminger IG.

J Hyg (Lond). 1976 Oct;77(2):173-80.

9.

Inactivated influenza vaccines. 2. Laboratory indices of protection.

Dowdle WR, Coleman MT, Mostow SR, Kaye HS, Schoenbaum SC.

Postgrad Med J. 1973 Mar;49(569):159-63. No abstract available.

10.

Antigenicity of influenza vaccine from bovine cell cultures.

Leiderman E, Mogabgab WJ.

Appl Microbiol. 1969 Oct;18(4):596-600.

11.

Purified influenza vaccine: clinical and serologic responses to varying doses and different routes of immunization.

Phillips CA, Forsyth BR, Christmas WA, Gump DW, Whorton EB, Rogers I, Rudin A.

J Infect Dis. 1970 Jul-Aug;122(1):26-32. No abstract available.

PMID:
5433710
12.

The potential role of immunological adjuvants in influenza vaccines.

Hobson D.

Postgrad Med J. 1973 Mar;49(569):180-84. No abstract available.

13.

Studies with inactivated influenza vaccines purified by zonal centrifugation. 2. Efficacy.

Schoenbaum SC, Mostow SR, Dowdle WR, Coleman MT, Kaye HS.

Bull World Health Organ. 1969;41(3):531-5.

14.

Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.

Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP.

Clin Infect Dis. 2009 Apr 15;48(8):1087-95. doi: 10.1086/597401.

15.

A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease.

Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright PF.

J Infect Dis. 1994 Jan;169(1):68-76.

PMID:
8277200
16.

Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience.

Neuzil KM, Dupont WD, Wright PF, Edwards KM.

Pediatr Infect Dis J. 2001 Aug;20(8):733-40.

PMID:
11734733
17.
18.

Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.

Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, Dunn J, DeStefano F, Shay D.

J Infect Dis. 2006 Oct 15;194(8):1032-9. Epub 2006 Sep 11.

19.

A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants.

Samdal HH, Bakke H, Oftung F, Holst J, Haugen IL, Korsvold GE, Kristoffersen AC, Krogh G, Nord K, Rappuoli R, Berstad AK, Haneberg B.

Hum Vaccin. 2005 Mar-Apr;1(2):85-90. Epub 2005 Mar 16.

PMID:
17038826
20.

The protective effect of intranasal immunization with inactivated influenza virus vaccine.

Lien KS, Jacobs J, Marcus EA, Strik RV.

Postgrad Med J. 1973 Mar;49(569):175-9. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk